FDA alignment on Phase 3 design removes a key regulatory uncertainty for zervimesine in DLB, a large unmet-need market. Monitor for protocol finalization, trial initiation, and potential partnership interest. The stock may re-rate on reduced binary risk, but clinical-stage biotech volatility remains high — position sizing should reflect that.
Price Chart
Executive Summary
Cognition Therapeutics announced FDA alignment on key elements of a pivotal Phase 3 trial of zervimesine (CT1812) in dementia with Lewy bodies (DLB), including patient selection, dose, duration, and endpoints. This de-risks the registrational path for a candidate that showed positive Phase 2 SHIMMER data, in a disease with no approved treatments. The news is a significant regulatory milestone for a $71M market cap clinical-stage biotech.
Key Facts
- FDA aligned on Phase 3 trial design for zervimesine (CT1812) in dementia with Lewy bodies (DLB)
- Phase 3 study will enroll mild-to-moderate DLB patients, randomized to 100 mg once-daily zervimesine or placebo for 9 months
- Primary endpoint: neuropsychiatric inventory measuring hallucinations and delusions (NPI2); key secondary: ADCS-ADL daily function scale
- Phase 2 SHIMMER study in DLB showed slowing of neuropsychiatric, cognitive, motor, and functional symptom progression
- DLB affects an estimated 1.4 million Americans with no approved treatments; more than half are never diagnosed
- Zervimesine is protected by a composition of matter patent expiring 2045
- Company has received nearly $200 million in NIH and foundation grants
Financial Impact
No financial figures provided in filing; company is pre-revenue clinical-stage. De-risking of Phase 3 pathway could significantly increase probability of success and partnership value.
Risk Factors
- Phase 3 trial may fail to meet primary or secondary endpoints despite promising Phase 2 data
- Enrollment in DLB trials can be challenging due to low diagnosis rates
- Company is pre-revenue with no approved products; requires additional financing to complete Phase 3
- Competition from other DLB and Alzheimer's candidates could emerge
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-117948 |
| Document: tm2628101d1_ex99-1.htm | 0001104659-26-117948 |
| Document: 0001104659-26-117948-index-headers.html | 0001104659-26-117948 |
| Document: 0001104659-26-117948-index.html | 0001104659-26-117948 |
| Document: 0001104659-26-117948.txt | 0001104659-26-117948 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $0.7010 $0.7188 | ▲ +2.54% | ▲ +3.06% | $0.7165 (+2.21%) |
Jun 4, 2026 20w ago | 8-K | $1.36 $1.29 | ▼ −5.15% | ▼ −2.55% | $0.7165 (−47.32%) |
Jun 1, 2026 21w ago | Press Release | $1.25 $1.35 | ▲ +8.00% | ▲ +7.86% | $0.7165 (−42.68%) |
May 21, 2026 22w ago | Press Release | $1.25 $1.26 | ▲ +0.80% | ▲ +0.35% | $0.7165 (−42.68%) |
May 14, 2026 23w ago | Press Release | $1.20 $1.14 | ▼ −5.00% | ▼ −3.77% | $0.7165 (−40.29%) |
May 7, 2026 24w ago | 8-K | $1.21 $1.18 | ▼ −2.48% | ▼ −2.71% | $0.7165 (−40.79%) |
Apr 16, 2026 27w ago | Insider Cluster | $1.11 $1.19 | ▲ +7.21% | ▲ +5.99% | $0.7165 (−35.45%) |
Mar 26, 2026 30w ago | Press Release | $1.08 $0.7300 | ▼ −32.41% | ▼ −30.73% | $0.7165 (−33.66%) |
Mar 23, 2026 31w ago | Press Release | $1.13 $1.10 | ▼ −2.65% | ▼ −2.30% | $0.7165 (−36.59%) |
Mar 17, 2026 31w ago | Press Release | $1.15 $1.10 | ▼ −4.35% | ▼ −2.95% | $0.7165 (−37.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers